Ovraian hyperstimulation sydrome(IVF-ET) OHSS
- 최초 등록일
- 2012.11.12
- 최종 저작일
- 2012.11
- 29페이지/
MS 파워포인트
- 가격 1,500원
소개글
IVF-ET 과정의 간략한 소개와 주된 부작용인 OHSS에대해 책과 논문으로 리뷰했습니다.
목차
1. IVF-ET
2. GnRH agonist & antagonist regime
3. OHSS pathophysiology
4. OHSS classification
5. OHSS risk factor
6. OHSS prevention
7. OHSS treatment
본문내용
IVF-ET (GnRH antagonist regimen)
1. Ovarian hyperstimulation 및 감시
Multiple follicular development
- Gonal-F (FSH)
- Menopur (hMG) : LH + FSH
“LH is critical to the overall development of ovarian follicle”
Prevention of premature LH surge
- Cetrotide (GnRH antagonist)
- when the lead follicle reaches 13-14mm in diameter or single dose on MCD 8
- lead follicles reaches 13~14mm in diameter, GnRH antagonist(cetrorelix or ganirelix 0.25mg)투여 매일 0.25mg 투여 (hCG 투여일까지)
Oocyte maturation
- Ovidrel (hCG)
- one of two leading follicles > 16-18mm,
or at least two other follicles > 14mm,
& serum estradiol levels 300-500pg/mL
참고 자료
Klaus Fiedler, Diego Ezcurra, Predicting and preventing ovarian hyperstimulation syndrome (OHSS) : the need for individualized not standardized treatment, Reproductive Biology and Endocrinology, 10:32, 2012
Hricak, Diagnostic Imaging : Gynecology, AMIRSYS, 2007
Jonathan S. Berek, Berek
대한산부인과학회, 부인과학(제4판), 도서출판 고려의학, 2007
